June 15 (Reuters) - AstraZeneca said on Tuesday its study of monoclonal antibody AZD7442 did not meet the main goal of preventing symptomatic COVID-19 in people recently exposed to the SARS-CoV-2 virus. (Reporting by Vishwadha Chander in Bengaluru; Editing by Shounak Dasgupta)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12,066 GBX | -0.74% | +7.33% | +14.09% |
01:18pm | Angle shares up on assay development deal with AstraZeneca | AN |
12:52pm | Angle shares up on assay development deal with AstraZenaca | AN |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.09% | 235B | |
+27.32% | 681B | |
+21.82% | 556B | |
-4.92% | 361B | |
+17.11% | 325B | |
+4.64% | 285B | |
+4.07% | 199B | |
-11.37% | 189B | |
-3.47% | 157B | |
+9.57% | 149B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca : says its antibody treatment failed in preventing COVID-19 in exposed patients